These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2723108)

  • 1. Effects of liver disease on the disposition of ciramadol in humans.
    Hoyumpa AM; Brown MW; Johnson R; Troxell R; Snowdy P; Schenker S
    J Clin Pharmacol; 1989 Mar; 29(3):217-24. PubMed ID: 2723108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic disposition of 14C-ciramadol in humans.
    Sisenwine SF; Liu AL; Tio C; Kimmel H; Freeland G
    Xenobiotica; 1986 Apr; 16(4):335-40. PubMed ID: 3754997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ciramadol glucuronidation by benzodiazepines.
    Meacham RH; Sisenwine SF; Liu AL; Kick CJ; Barinov I; Ruelius HW
    Drug Metab Dispos; 1986; 14(4):430-6. PubMed ID: 2873990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disposition of ciramadol in rhesus monkeys and rats.
    Sisenwine SF; Tio CO; Ruelius HW
    Drug Metab Dispos; 1982; 10(2):161-7. PubMed ID: 6124403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.
    Macdonald JI; Wallace SM; Mahachai V; Verbeeck RK
    Eur J Clin Pharmacol; 1992; 42(5):471-4. PubMed ID: 1606992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of the human kidney to the metabolic clearance of drugs.
    Vree TB; Hekster YA; Anderson PG
    Ann Pharmacother; 1992 Nov; 26(11):1421-8. PubMed ID: 1477449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary pharmacokinetics of intravenous ciramadol in humans.
    Rosseel MT; Bogaert MG; Oosterlinck W
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):304-6. PubMed ID: 6547699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis.
    Orlando R; Floreani M; Napoli E; Padrini R; Palatini P
    Nephron; 2000 Jan; 84(1):32-9. PubMed ID: 10644906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered disposition and availability of cimetidine in liver cirrhotic patients.
    Gugler R; Müller-Liebenau B; Somogyi A
    Br J Clin Pharmacol; 1982 Sep; 14(3):421-30. PubMed ID: 7126415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.
    Shull HJ; Wilkinson GR; Johnson R; Schenker S
    Ann Intern Med; 1976 Apr; 84(4):420-5. PubMed ID: 769632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
    Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
    J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cimetidine administration and tubular creatinine secretion in patients with compensated cirrhosis.
    Sansoè G; Ferrari A; Castellana CN; Bonardi L; Villa E; Manenti F
    Clin Sci (Lond); 2002 Jan; 102(1):91-8. PubMed ID: 11749665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral ciramadol: a new analgesic for postoperative pain.
    Reines HD; Hunt P; Rambo W; Loadholt CB
    J Clin Pharmacol; 1986 Feb; 26(2):111-4. PubMed ID: 3753988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced renal clearance of uric acid in hepatic cirrhosis.
    Higuchi T; Nakamura T; Uchino H
    Isr J Med Sci; 1981 Nov; 17(11):1015-8. PubMed ID: 7319788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
    Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
    Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciramadol. The therapeutic dose range during balanced anesthesia.
    Camu F; Heytens L; Claeys MA
    Acta Anaesthesiol Belg; 1985 Mar; 36(1):23-31. PubMed ID: 3839340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cimetidine in advanced cirrhosis.
    Grahnén A; Jameson S; Lööf L; Tyllström J; Lindström B
    Eur J Clin Pharmacol; 1984; 26(3):347-55. PubMed ID: 6734697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of food on ciramadol bioavailability in normal subjects.
    Audet PR; Chiang S; Maroli A; Locniskar A; Morrison G
    Biopharm Drug Dispos; 1987; 8(3):299-304. PubMed ID: 3593906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.